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The role of monocytes/macrophages in the develop-
ment and progression of chronic lymphocytic leu-
kemia (CLL) is poorly understood. Transcriptomic
analyses show that monocytes/macrophages and
leukemic cells cross talk during CLL progression.
Macrophage depletion impairs CLL engraftment,
drastically reduces leukemic growth, and favorably
impacts mouse survival. Targeting of macrophages
by either CSF1R signaling blockade or clodrolip-
mediated cell killing has marked inhibitory effects
on established leukemia also. Macrophage killing
induces leukemic cell death mainly via the TNF
pathway and reprograms the tumor microenviron-
ment toward an antitumoral phenotype. CSF1R
inhibition reduces leukemic cell load, especially in
the bone marrow, and increases circulating CD20+
leukemic cells. Accordingly, co-targeting TAMs and
CD20-expressing leukemic cells provides a sur-
vival benefit in the mice. These results establish the
important role of macrophages in CLL and suggest
therapeutic strategies based on interfering with leu-
kemia-macrophage interactions.1748 Cell Reports 14, 1748–1760, February 23, 2016 ª2016 The AuthINTRODUCTION
The interactive co-evolution of cancer and normal bystander
cells optimizes the clonal expansion of chronic lymphoid ma-
lignancies of B cell type within specific microenvironments.
Chronic lymphocytic leukemia (CLL) is the most frequent and
paradigmatic chronic B cell malignancy, characterized by the
growth of mature CD5+ monoclonal B lymphocytes in immune-
protected and protumorigenic habitats that include stromal, T,
and endothelial cells (Caligaris-Cappio et al., 2014; Caligaris-
Cappio and Ghia, 2008; Zenz et al., 2010). CLL cells accumu-
lating in peripheral lymphoid organs, bone marrow (BM), and
circulating in peripheral blood (PB) are the progeny of cells that
proliferate in specific tissue microenvironmental niches, termed
pseudofollicles (Caligaris-Cappio et al., 2014).
CLL cell cross talk with themicroenvironment is largely depen-
dent upon a functional leukemic B cell receptor (BCR). Signaling
through the BCR modulates CLL cell proliferation, survival, and
cytoskeletal activity and can be targeted by inhibitors that, by
interfering with different BCR-associated kinases such as Bruton
tyrosine kinase (BTK), also influence the interaction betweenCLL
cells and themicroenvironment (Burger and Gribben, 2014; Byrd
et al., 2013). For example, the BTK inhibitor ibrutinib blocks the
protective functions of stromal cells (Herman et al., 2011), which
deploy signals that favor the survival of CLL cells (Lutzny et al.,
2013).ors
Figure 1. BM Microenvironment of Xeno-
transplanted Mice: Monocyte and Macro-
phage Populations
(A–F) Rag2/gc/ mice, uninjected (UN, black
circles) or injected i.v. with MEC1 (white circles)
cells (day 0), were killed at early (n = 3) and late (n =
3) stage of leukemia and analyzed by flow cy-
tometry (A). The mean value of the relative contri-
bution of hCD19+ cells in BM is shown in (B). The
mean value of the absolute number of CD11b+
CSF1R+ cells gated on CD45+ in BM is shown in
(C). The mean value of the absolute number of
CD11b+ F4/80+ cells gated on CD45+ in BM is
shown in (D). The mean value of the absolute
number of CD11b+ MRC1+ cells to the whole
macrophage pool (CD11b+ F4/80+) gated on
CD45+ in BM is shown in (E). Data are from one
representative experiment out of three. Statistical
analysis: *p < 0.05, **p < 0.01, and ***p < 0.001,
Student’s t test.
(F) The mean value of the absolute number
of CD86+ MRC1+ and CSF1R+ MRC1+ cells
to the whole CD45+ CD11b+ pool in BM is
shown. Statistical analysis: *p < 0.05, Student’s
t test.
See also Figure S1.A role for monocyte/macrophage cells in CLL has been
suggested by a number of in vitro and correlative studies.
The survival of leukemic cells is supported in vitro by nurse-
like cells (NLCs) that are induced upon coculturing PB or
spleen monocytes with CLL cells (Tsukada et al., 2002).
NLCs share lineage and functions with lymphoma-associated
macrophages described in other B cell tumors and have
been identified as CLL-specific tumor-associated macro-
phages (TAMs) (Filip et al., 2013). The gene expression profile
(GEP) of CLL cells exposed in vitro to NLCs (Burger et al.,
2009) is strikingly similar to that of CLL cells isolated from
lymph nodes (Herishanu et al., 2011). Moreover, the absence
of macrophage migration inhibitory factor (MIF) was shown
to delay the development of leukemia in the Em-TCL1 trans-
genic mouse model of CLL (Bichi et al., 2002; Reinart et al.,
2013).
Prompted by these observations, we sought to investigate
the mechanisms whereby TAMs regulate leukemic cell growth
in vivo by employing different CLL transplantation mouse
models and TAM depletion strategies. In particular, we em-
ployed a cell-killing approach based on the macrophage
uptake of clodronate (Acquati et al., 2011; van Rooijen and
Hendrikx, 2010) and an anti-colony-stimulating factor-1 recep-
tor (CSF1R) monoclonal antibody (mAb). The therapeutic anti-
CSF1R mAb emactuzumab (RG7155) inhibits macrophageCell Reports 14, 1748–1760, Fdifferentiation from monocyte precur-
sors and is emerging as clinical tool to
target macrophages (Ries et al., 2014;
Ruffell and Coussens, 2015). Our find-
ings demonstrate that TAMs critically
support the survival and proliferation
of CLL cells in vivo, therefore unveilingtherapeutic strategies based upon manipulating TAM/CLL-
cell interactions.
RESULTS
Characterization of BM Monocytes and Macrophages in
CLL Xeno-transplanted Mice
We asked whether monocytes/macrophages influence CLL
growth in the BM. Eight-week-old Rag2/gc
/ mice were
injected intravenously (i.v.; day 0) with MEC1 cells (a CLL cell
line) (Bertilaccio et al., 2010) and killed either in the early (day
21) or overt (day 31) phase of leukemia growth (Figure 1A),
when the percentage of human CD19+ leukemic cells in the
BM was 33.83 ± 15.03 and 86 ± 9.13, respectively (Figure 1B).
We found lower numbers of CD11b+CSF1R+ monocytes and
CD11b+F4/80+ macrophages in the BM of frank leukemic
Rag2/gc
/mice when compared to early leukemic mice (Fig-
ures 1C and 1D). While the total F4/80+ macrophage population
decreased, the abundance of CD11b+ cells coexpressing the
macrophage mannose receptor (MRC1/CD206), CSF1R, and
CD86 increased along with leukemia progression (Figures 1E
and 1F), a feature also associated with progression of solid
tumors (De Palma and Lewis, 2013; Noy and Pollard, 2014).
To specifically characterize the molecular profile of CLL-
associated monocytes/macrophages (Figures 1C and 1D), aebruary 23, 2016 ª2016 The Authors 1749
Figure 2. Effect of Clodrolip-Mediated Macrophage Depletion in
CLL Transplantation Systems
(A–D) Rag2/gc/ mice, injected i.v. with MEC1 cells (day 0) and macro-
phage-depleted by i.v. injection of PBS liposomes (200 ml, black circles, C) or
clodrolip (200 ml, white circles, clo) every 3 days starting at day 1 were
sacrificed at day 28 (A). Histology of spleen is shown (one representative
mouse): H&E staining and immunohistochemistry stain for murine F4/80; scale
bars, 100 mm (B). Spleens from control and clodrolip-treated mice were
collected and analyzed macroscopically; for control mice, half the spleen is
shown (C). The mean value of the relative contribution of hCD19+ cells in
SP, BM, PB, and PE is shown in graph (D). Data are from two independent
1750 Cell Reports 14, 1748–1760, February 23, 2016 ª2016 The Authwhole-genome transcriptional profile analysis was performed by
Illumina hybridization system on monocytes/macrophages iso-
lated from the BM of Rag2/gc/ xeno-transplanted mice,
sacrificed at day 21 (early leukemia). A complex network of
gene regulation involving the modulation of 164 transcripts (84
up- and 80 downregulated; 1.6% of total transcripts; adjusted
p value < 0.05) distinguished monocytes/macrophages of mice
with leukemia compared to age-matched, uninjected mice
(Table S1). Differentially expressed genes were organized into
five putative functional categories including inflammation and
intracellular/extracellular function, shown in Figures S1A–S1E.
In parallel, we also analyzed the transcriptional changes
occurring in leukemic MEC1 cells purified from the same mice.
Particularly relevant was the differential expression of genes
supporting the existence of monocyte/macrophage-leukemic
cell cross talk, including IL10, RNASET2, and CCL2 (a potent
monocyte chemoattractant; Noy and Pollard, 2014), besides
genes involved in CLL progression, like NOTCH1, BIRC3, and
PTEN (Figure S1F). Due to its role in B cell adhesion, antigen pre-
sentation, and activation (Batista and Harwood, 2009), we vali-
dated ICAM1 upregulation at the protein level, both in mouse
macrophages from spleen (SP), BM, or peritoneal exudate (PE)
(Figure S1G) and human classical monocytes of CLL patients
(Figure S2A). Xeno-transplantation studies using an anti-mouse
ICAM1 blocking mAb, administered every 3/4 days from day
1 (Figure S2B), demonstrated that its inhibition increased the
number of leukemic cells in the PB, SP, and PE, but not in the
BM (Figure S2C), thus suggesting a functional relevance of
ICAM1 upregulation in different tissues. We also confirmed by
qPCR the differential expression of a panel of selected genes
in both murine monocytes/macrophages (Figure S2D) and hu-
man MEC1 cells (Figure S2E).
Taken together, these findings indicate that CLL cells
profoundly sculpt the BM microenvironment and modulate the
expression of multiple gene transcripts involved in CLL cell-
monocyte/macrophage interaction.
Macrophage Depletion Impairs CLL Grafting in Mice
The aforementioned analyses led us to investigate whether CLL
engraftment and progression in mice might be affected by
the absence of monocytes/macrophages. To address this ques-
tion, we depleted macrophages in MEC1-grafted Rag2/gc
/
mice by i.v. administration of clodronate liposomes (clodrolip)
every 3 days from day 1 (Figure 2A), as described previouslyexperiments (n = 6/group). Statistical analysis: *p < 0.05, **p < 0.01, and ***p <
0.001, Student’s t test.
(E–K) C57BL/6 mice transplanted i.p. with leukemic B cells from Em-TCL1
transgenic mouse, pretreated i.p. (day 1) with 200 ml PBS liposomes (n = 4,
black circles) or with clodrolip (n = 4, white circles), were analyzed by flow
cytometry (E). The mean value of the relative contribution of CD19+ CD5+ cells
to the whole B cell pool in PB over time is shown (F). The mean value of the
relative contribution of CD11b+ CSF1R+ cells gated on CD45+ in PB is shown
(G). The mean value of the absolute number of CD11b+ F4/80+ cells gated on
CD45+ in PE and SP is shown in (H) and (I), respectively. The mean value of the
relative contribution of CD19+ CD5+ cells to the whole B cell pool in SP, BM,
lymph node (LN) (J), and PB and PE (K) at day 29 is shown. Data are from one
representative experiment of two. Statistical analysis: *p < 0.05, **p < 0.01, and
***p < 0.001, Student’s t test.
ors
Figure 3. Monocyte/Macrophage Killing Approach in CLL Xenograft Systems at the Preclinical Level
(A–G) Rag2/gc/ mice transplanted s.c. with MEC1 cells were treated s.c. at the LN site (days +39, +45, +52, +56, +60, +63, and +66) with 50 ml of PBS
liposomes (n = 5, black circles) or clodrolip (n = 5, white circles) (A). A representative mouse (day 48) with its tumor (dashed line) and LN (continuous line) growth
curves are shown for PBS liposomes (B and C) and clodrolip (D and E). Tumor and LN volumes (mean ± SD) are shown (F). Statistical analysis was performed
using the Student’s t test (*p < 0.05, **p < 0.01, and ***p < 0.001; measurements were stopped when 60% of mice were still surviving). These two groups of mice
were monitored for survival (G). Kaplan-Meier survival curve is shown, statistical analyses was performed using the log-rank test (***p < 0.001). Data are from one
representative experiment of two.
(H and I) i.v. MEC1 challenged (day 0) Rag2/gc/micewere treated i.v. (days +10, +14, +17, and +20) with 60 ml PBS liposomes (n = 3, black circles) or clodrolip
(n = 3, white circles) and killed at day 32 (H). The mean value of the absolute number of hCD19+ cells in the BM is shown in graph (I). Statistically significant
differences were calculated using the Student’s t test (**p < 0.01).
(legend continued on next page)
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(Sunderko¨tter et al., 2004). Mice were sacrificed at late stage
of the disease, 17 days after the last clodrolip injection, when
untreated mice developed signs of overt leukemia (e.g., weight
loss). Clodrolip-mediated macrophage depletion (Figure 2B)
was associated with a significant reduction of leukemic cell
burden in the SP, BM, PB, and PE (Figures 2C and 2D).
To extend these findings to an immunocompetent mouse
model, we transplanted leukemic cells from the spleen of
Em-TCL1 transgenic mice intraperitoneally (i.p.) into syngeneic
immunocompetent recipients (Figure 2E), as described previ-
ously (Zanesi et al., 2006). A progressive expansion of the
leukemic clone was detected in the PB of the transplanted
mice after 3–4 weeks (Figure 2F). When the mice were macro-
phage-depleted by i.p. clodrolip injection, starting at day 1
(Figure 2E), a significantly lower number of leukemic B cells
was observed in the PB over time (Figure 2F). Upon necropsy
(day 29, 11 days after the last clodrolip injection), comparative
analyses of clodrolip-treated and untreated mice showed that
the depletion of monocytes (Figure 2G) and macrophages (Fig-
ures 2H and 2I) was associated with a reduction of the leukemic
clone in lymphoid tissues (Figure 2J), PB, and especially PE
(Figure 2K).
These findings suggest that monocytes/macrophages sup-
port the growth of CLL cells in mice.
Induced Monocyte/Macrophage Death Improves the
Survival of Leukemic Mice
We then asked whether interfering with leukemic cell-macro-
phage interactions might translate into a survival benefit in CLL
models. In a first set of experiments, clodrolip was administered
to MEC1-injected Rag2/gc
/ mice with advanced disease.
Rag2/gc
/mice transplanted with subcutaneous tumors car-
rying visible leukemic lymph nodes (LN) were repeatedly injected
subcutaneously (s.c.) with clodrolip, in proximity to the LN
(Figure 3A). Compared to untreated mice (Figures 3B and 3C),
clodrolip greatly reduced the LN size already after the second
clodrolip administration (Figures 3D and 3E). Clodrolip treatment
inhibited LN and primary tumor growth (Figure 3F) and extended
mouse survival (Figure 3G, p = 0.0008; Figures S3A–S3G).
Furthermore, when clodrolip was administered i.v. (four injec-
tions every 3 days) to systemically xeno-transplanted mice start-
ing at day 10 after leukemic challenge (Figure 3H), it induced a
significant reduction of hCD19+ leukemic cells, especially in
the BM (Figure 3I). Of note, two systemic administrations of
clodrolip (Figure S3H) were sufficient to deplete macrophages
(Figures S3I and S3J), reduce the leukemic expansion (Figures
S3K and S3L), and significantly extend the survival of xeno-
transplanted mice (Figures 3J and 3K).
To further test the anti-leukemic activity of clodrolip, we trans-
planted i.p. leukemic cells obtained from the spleenof anEm-TCL1
transgenic mouse in syngeneic immunocompetent recipients.
Starting at day 16 post-transplantation, the mice were injected
i.p. with clodrolip every 4 days with suboptimal (non-exhaustively(J and K) i.v. MEC1 challenged (day 0) Rag2/gc/ mice were treated i.v. (da
(n = 7, white circles) and monitored for survival (J). The Kaplan-Meier survival cur
(***p < 0.001).
See also Figure S3.
1752 Cell Reports 14, 1748–1760, February 23, 2016 ª2016 The Authdepleting; 50ml/mouse) dosesof clodrolip and sacrificedat day 28
(Figure S3M). As shown in Figures S3N and S3O, CD11b+F4/80+
macrophages were reduced in the SP and PE. We observed a
significantly lower number of leukemic B cells in the PB over
time (Figure S3P). A significantly lower frequency of leukemic
B cells was observed in the SP, PB, and PE after four clodrolip
doses (Figures S3Q and S3R), along with a significant increase
of CD19+CD5+AnnV+ early apoptotic cells in the PE, the site of
leukemic cell and clodrolip injection (Figure S3S).
In conclusion, clodrolip-mediated macrophage killing is asso-
ciated with a drastic reduction of CLL growth in two mouse
models of the disease.
TargetingMonocytes/Macrophages byCSF1R Inhibition
Can Be Exploited as a Therapeutic Strategy in CLL
To evaluate the therapeutic potential of macrophage targeting,
we investigated the anti-leukemic effects of a monoclonal anti-
body that inhibits CSF1R signaling and prevents macrophage
differentiation from monocyte precursors (Ries et al., 2014).
Rag2/gc
/ mice transplanted i.v. with MEC1 cells were in-
jected i.v. with the anti-mouse CSF1R mAb 2G2 (30 mg/kg,
days +11 and +25) and sacrificed at day 27, 48 hr after the last
mAb injection (Figure 4A). Macrophage depletion (Figures 4B
and 4C) significantly reduced the number of leukemic B cells in
the BM (Figure 4D) and induced the appearance of CD19+
AnnVPI+ necrotic leukemic cells in the SP (Figure 4E). To
confirm that CSF1R blockade reduces disease severity in the
SP, we performed a time course experiment, where mice were
sacrificed 48 hr and 96 hr after the last mAb injection, at days
27 and 29, respectively (Figure 4F). CSF1R blockade was able
to stabilize the disease and induce increasing necrosis of the
splenic leukemic cells over time (Figure 4G). This anti-leukemic
effect was associated with a remarkable and selective depletion
of CSF1R+ MRC1+ M2-like TAMs (Figures 4H and 4I).
As already shown in solid tumors (Ries et al., 2014), CSF1R
blockade, together with monocyte depletion (Figures S4A and
S4B), induced a relative increase in the PB of SSChigh neutrophil
granulocytes (Figure S4C) and Gr1+ myeloid cells (Figure S4D)
encompassing both monocytic (Ly6C+) and granulocytic
(Ly6G+) subsets (Figures S4E and S4F). Of note, this effect was
not observed with clodrolip (Figures S4G–S4K). In the BM,
CSF1R blockade decreased monocytes, identified as either
CD11b+CSF1R+ (Figure S4L) or Ly6C+ (Figures S4M and S4N).
In the Em-TCL1 tg transplantation model (Figure S4O), we
observed a pronounced increase of CD8+ effector T cells in the
PB (Figure S4P), BM (Figure S4Q), and SP (Figures S4R and
S4S), accompanied by a marked increase of apoptotic leukemic
cells (Figure S4T) and a decrease of splenic CD4+CD25+ T cells
(Figure S4U). Conversely, clodrolip did not impact T cells (Fig-
ures S4V–S4X).
Two administrations of the anti-CSF1R mAb (Figure 5A)
induced significant lymphocytosis (Figure 5B), a treatment-
related compartment shift from infiltrated tissues into PB,ys +11 and +25) with 60 ml PBS liposomes (n = 6, black circles) or clodrolip
ve is shown (K), and statistical analysis was performed using the log-rank test
ors
Figure 4. Anti-leukemic Effect of Anti-CSF1R mAb in the CLL
Xeno-transplantation System
(A–E) i.v. MEC1 challenged (day 0) Rag2/gc/ mice were treated i.v.
(days +11 and +25) with 30 mg/kg anti-CSF1R mAb (n = 3, white circles) or left
untreated (n = 4, black circles) and killed at day 27 (A). The mean value of the
absolute number of CD11b+ F4/80+ cells gated on CD45+ in SP (B) and BM (C)
is shown. The mean value of the absolute number of human CD19+ cells in the
BM is shown (D). Themean value of the absolute number of humanCD19+ cells
and of AnnVPI+ cells gated on hCD19+ cells in SP is shown (E).
Data are from one representative experiment of three. Statistical analysis:
*p < 0.05 and **p < 0.01, Student’s t test.
(F–I) i.v. MEC1 challenged (day 0) Rag2/gc/ mice were treated i.v.
(days +11 and +25) with 30 mg/kg anti-CSF1R mAb (n = 7, white circles) or left
untreated (n = 7, black circles) and killed at days 27 and 29, 48 hr and 96 hr after
the last mAb injection (F). The mean value of the absolute number of human
Cell Ralready seen in CLL patients with agents targeting BCR signaling
(e.g., ibrutinib), which does not indicate disease progression
(Byrd et al., 2013). As mAb treatment increased the percentage
of CD19+CD20+ circulating leukemic cells (Figure 5C), we tested
a two-pronged approach by combining the anti-CSF1R mAb
with the glycoengineered type II CD20 mAb, GA101 (Mo¨ssner
et al., 2010) (Figure 5D). Of note, anti-mouse CSF1R mAb favor-
ably impacted on the survival of mice as single agent (p = 0.0056,
aCSF1R mAb versus untreated) and even more significantly
in combination settings (p = 0.0082, aCD20 / aCSF1R mAb
versus aCD20 mAb; p = 0.01, aCSF1R/ aCD20 mAbs versus
aCD20 mAb) (Figure 5E).
Considering the reduced CD20 expression on CLL cells
and their impaired susceptibility to anti-CD20 mAbs observed
in ongoing clinical studies combining anti-CD20 mAbs and
promising new drugs such as ibrutinib (Skarzynski et al.,
2015), the additive therapeutic effect of CSF1R inhibition
and anti-CD20 mAb we here describe pave the way toward
important therapeutic strategies for CLL and B lymphoid
malignancies.
Leukemic Cell Death Induced by Macrophage Targeting
Is TNF Dependent
As a next step we evaluated how leukemic cells were affected
by macrophage targeting. Clodrolip and anti-human CSF1R
mAb have no direct toxicity on leukemic B cells in vitro, as
shown by cytotoxicity assays performed on MEC1 cells (Fig-
ure S5A). We therefore investigated alternative mechanisms
whereby clodrolip and anti-CSF1R may induce leukemic cell
death in vivo. To address this question, Rag2/gc/ mice
transplanted i.v. with MEC1 cells were macrophage-depleted
by i.v. clodrolip injection every 3 days starting at day 1
(7 consecutive injections) and sacrificed 1 day after the last
treatment (Figure 6A). The reduction of the leukemic (Fig-
ure 6B) and monocyte/macrophage (Figures 6C–6E) cell
burden induced by clodrolip paralleled the induction of
apoptosis of leukemic cells in all tissues, as shown by the
significantly increased frequency of CD19+ AnnV+PI+ late-
apoptotic cells in the SP and BM and of CD19+ AnnVPI+
necrotic cells in the PB (Figures 6F and 6G). These results
confirmed the increase of CD19+ AnnVPI+ necrotic cells
already observed in the SP of anti-CSF1R mAb-treated
mice (Figure 4G). The interaction between leukemic B cells
and monocytes/macrophages (Movies S1 and S2) and the
induction of leukemic B cells apoptosis upon clodrolip
(Movie S3) were also visualized in a time-course experi-
ment whereby GFP-labeled monocytes/macrophages were
added to leukemic cells from Em-TCL1 transgenic mice in
the absence or presence of clodrolip. Interestingly, annexinCD19+ cells and of AnnVPI+ cells gated on hCD19+ cells in SP at days 27 and
29 is shown (G). The mean value of the absolute number of CD11b+ F4/80+
cells gated on CD45+ in SP at day 27 is shown (H). The mean value of the
absolute number of CD11b+ MRC1+ cells to the CSF1R+ macrophage pool
gated on CD45+ in SP at day 27 is shown (I).
Data are from one representative experiment of two. Statistical analysis:
*p < 0.05, Student’s t test.
See also Figure S4.
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Figure 5. Anti-leukemic Effect and Survival
Impact of Anti-CSF1R mAb in the CLL
Xeno-transplantation System
(A–C) i.v. MEC1 challenged (day 0) Rag2/gc/
mice were treated i.v. (days +11 and +25) with
30 mg/kg anti-CSF1R mAb (n = 3, white circles) or
left untreated (n = 4, black circles) and killed at day
27 (A). The mean value of the percentage of
hCD19+ (B) and of hCD19+ CD20+ (C) cells in PB
is shown in graphs.
Data are from one representative experiment
of two. Statistically significant differences were
calculated using the Student’s t test (**p < 0.01 and
***p < 0.001).
(D and E) i.v. MEC1 challenged (day 0)
Rag2/gc/ mice were left untreated (n = 14,
black circles) or treated with 30 mg/Kg i.v. anti-
CSF1R mAb (n = 15, white circles; days +11
and +25) or 30 mg/kg i.p. anti-CD20 mAb
GA101 (n = 14, blue circles; days +11 and +25)
or 30 mg/kg i.p. anti-CD20 mAb GA101
(day +11, +25) + 30 mg/kg i.v. anti-CSF1R mAb
(days +18 and +32) (n = 14, full violet circles) or
30 mg/kg i.v. anti-CSF1R mAb (days +11
and +25) + 30 mg/kg i.p. anti-CD20 mAb GA101
(days +18 and +32) (n = 4, empty violet circles) and
monitored for survival (D). The Kaplan-Meier sur-
vival curve is shown (E), and statistical analysis
was performed using the log-rank test. aCSF1R
versus control: p = 0.0056; aCD20 versus control:
p = 0.0003; aCD20 / aCSF1R versus control:
p < 0.0001; aCD20/ aCSF1R versus aCD20: p =
0.0082; aCSF1R / aCD20 versus control:
p = 0.0005; aCSF1R / aCD20 versus aCD20:
p = 0.01.V/propidium iodide (AnnV/PI) staining and flow cytometry
analysis showed that the induction of leukemic cell apoptosis
by clodrolip occurred only in the presence of monocytes and
macrophages (Figure S5B).
To investigate the cell death pathways induced in leukemic
cells via clodrolip-mediated macrophage killing, we purified
CD19+ MEC1 cells from the BM of transplanted Rag2/gc
/
mice and evaluated, at the RNA level by qPCR, the expression1754 Cell Reports 14, 1748–1760, February 23, 2016 ª2016 The Authorsof key effector molecules involved in
TNF-, TRAIL-, reactive oxygen species
(ROS)-, and FAS/FASL-regulated cell
death pathways. As for the TNF pathway,
we observed upregulated expression of
TNFR1, FADD, BID, BAX, and CASP3
(Figure S5C). Interestingly we also found
upregulated levels of TRAIL-R2 and
AIFM1 (Figure S5C), the latter being
involved in ROS-mediated dell death
(Joza et al., 2009).
To confirm the involvement of TNF (Fig-
ure S5C) in the mechanism of leukemia
cell death induced bymacrophage target-
ing, we utilized etanercept, a soluble TNF
receptor fusion protein (Deeg et al., 2002),
in xeno-transplanted Rag2/gc
/ micetreated either with clodrolip or CSF1R mAb. Rag2/gc
/
mice transplanted i.v. withMEC1 cells and injectedwith clodrolip
(i.v., days +11 and +25) and with etanercept (i.p., starting at
day +10) were sacrificed 24 hr after the last clodrolip injection
(Figure 6H). Etanercept partially rescued clodrolip-induced
leukemic cell depletion in the BM (Figure 6I).
In xeno-transplanted mice treated i.v. with the CSF1R mAb
(days +11 and +25) and sacrificed 96 hr after the last injection
Figure 6. TNF-Dependent Macrophage-
Mediated Mechanism of In Vivo Leukemic
Cell Death
(A–G) i.v. MEC1 challenged (day 0) Rag2/gc/
mice were either pretreated starting from day 1
every 3 days with 200 ml i.v. clodrolip (n = 4, white
circles) or left untreated (n = 3, black circles) and
were analyzed by flow cytometry (A). The mean
value of the percentage of human CD19+ cells in
SP, BM, PB, and PE is shown (B). The mean value
of the relative contribution of CD11b+ CSF1R+ cells
gated on CD45 in PB is shown (C). The mean value
of the absolute number or of the percentage of
CD11b+ F4/80+ cells gated on CD45 in SP, BM, PE
(D), and PB (E) is shown. The mean value of the
relative contribution of AnnV+ PI+ cells gated on
hCD19+ cells in SP, BM, and PE (F) and of the
relative contribution of AnnV PI+ cells gated on
hCD19+ cells in PB (G) is shown. Statistical sig-
nificance was analyzed by Student’s t test (*p <
0.05, **p < 0.01, and ***p < 0.001).
(H and I) i.v. MEC1 challenged (day 0)
Rag2/gc/ mice were left untreated (n = 6,
black circles) or treated i.v. (days +11 and +25) with
60 ml clodrolip (n = 4, white circles) or with 60 ml
clodrolip (days +11 and +25) + 10 mg/kg eta-
nercept (i.p., days +10, +12, +15, +18, +21,
and +24) (n = 6, red triangles) and killed at day 26
(H). The mean value of the absolute number of
human CD19+ cells in the BM is shown (I).
Statistical significance was analyzed by Student’s
t test (*p < 0.05, **p < 0.01, and ***p < 0.001).
(J and K) i.v. MEC1-challenged (day 0)
Rag2/gc/ mice were left untreated (n = 5,
black circles) or treated i.v. (days +11 and +25)
with 30 mg/kg anti-CSF1R mAb (n = 7, white
circles) or with 30 mg/kg anti-CSF1R mAb
(days +11 and +25) + 10 mg/kg etanercept
(i.p., days +10, +12, +15, +18, +21, and +24) (n = 6,
red triangles) and killed at day 29 (J). The mean
value of the absolute number of human CD19+
cells in the SP is shown in graph (K).
Statistical significance was analyzed by Student’s
t test. *p < 0.05.
See also Figure S5 and Movies S1, S2, and S3.of the mAb (Figure 6J), the anti-leukemic effect was abrogated in
the SP when TNF pathway was blocked in vivo by etanercept
(Figure 6K).Cell Reports 14, 1748–1760, FFurthermore, we functionally inacti-
vated the FAS/FASL signaling by using
the blocking antibody clone Kay-10 (Bio-
Legend) in the Em-TCL1 tg transplanta-
tion system. FASL blocking did not
abrogate the leukemic cell depletion of
transplanted mice treated with clodrolip
(Figures S5D–S5G) or with aCSF1R (Fig-
ures S5H–S5J). The same clodrolip re-
sults were confirmed by transplanting
leukemic B cells into Faslgldmice, carrying
a null-function mutation of the Fasl gene
(Figures S5E–S5G).These findings let us conclude that macrophage killing sensi-
tizes leukemic cells to apoptosis mainly via induction of TNF
signaling.ebruary 23, 2016 ª2016 The Authors 1755
Figure 7. Monocytes/Macrophages and
Leukemic Cells in Humans
(A) Immunohistochemistry stain for human CD68
and Ki67 in two representative lymph node sec-
tions from CLL patients. Scale bars, 20 mm.
(B) Human primary CLL cells obtained from CLL
patients (n = 4, patients #19–22) were plated in
96-well plates alone (c), with increasing concen-
trations of clodrolip (10 mM, 100 mM, and 1,000 mM)
or with PBS liposomes (v, 1,000 mM) and a lumi-
nescent assay was performed 24, 48, and 72 hr
later to evaluate primary CLL cell sensitivity to the
drug (b, background).
(C and D) hCD19+ CD5+ (black circles) and hCD14+
(white circles) depletion after 30 min (C, n = 8) and
24 hr treatment (D), n = 8) with 100 mM, 500 mM, or
1,000 mM clodrolip was calculated by the following
formula: 100 - % remaining cells, where % remain-
ing cells = (Absolute number in treated samples/
Absolute number in untreated samples) 3 100.
Horizontal bars represent themean value (*p < 0.05,
**p < 0.01, and ***p < 0.001, Student’s t test).
(E) Unseparated PBMCs from CLL patients #20
and #23 in 12-well plates after 30-min treatment
with 1,000 mM clodrolip or empty liposomes were
photographed with Nikon microscope. Scale bars,
100 mm.
(F) Human primary CD14+ cells obtained from CLL
patients (n = 4) were separated from total PBMCs,
seeded or not on a transwell chamber (0.4 mmpore
size) with 1,000 mM clodrolip or PBS liposomes,
while the remaining CD14 PBMCs or total
PBMCs were seeded in the lower part of the
chamber. CD19+ CD5+ cell depletion (mean ± SD)
of unseparated PBMCs (black bar), PBMCs with
separated monocytes (gray bar), and PBMCs
without monocytes (white bar) after 24 hr treat-
ment was calculated by the following formula:
100  % remaining cells, where % remaining
cells = (Absolute number in treated samples/
Absolute number in untreated samples) 3 100.
**p < 0.01 and ***p < 0.001, Student’s t test
(G) hCD19+ CD5+ (black circles) and hCD14+
(white circles) depletion after 48 hr (n = 4) with anti-
CD20 mAb GA101 10 mg/ml, anti-human CSF1R
mAb RG7155 (1–10 mg/ml), anti-CD20 mAb GA101
10 mg/ml + anti-human CSF1R mAb RG7155
(1–10 mg/ml) was calculated by the following for-
mula: 100  % remaining cells, where % remain-
ing cells = (Absolute number in treated samples/
Absolute number in untreated samples) 3 100.
Horizontal bars represent the mean value (*p <
0.05 and **p < 0.01, Student’s t test).
See also Figure S6.Targeting Human Primary CLL Cells by
Monocyte/Macrophage Killing
Finally, we applied the relevant molecular and functional infor-
mation gathered in mouse models to human samples. We first1756 Cell Reports 14, 1748–1760, February 23, 2016 ª2016 The Authorsanalyzed by immunohistochemistry LN
sections from CLL patients and observed
the proximity of CD68+ macrophages to
proliferating (Ki67+) CLL cells in the prolif-eration centers (Figure 7A). As a next step, we evaluated whether
human primary leukemic cells could be affected by clodrolip.
Clodrolip had no direct toxic effect in vitro on leukemic B cells,
as shown by cytotoxicity studies performed on MEC1 cells
(Figure S5A) as well as on purified human primary CLL cells (Fig-
ure 7B). However, when unfractionated peripheral blood mono-
nuclear cells (PBMCs) of CLL patients (which contained both
leukemic and normal hematopoietic cells) were treated with
different doses of clodrolip, we observed a marked depletion
of both CD14+ monocytes and leukemic B cells, as early as
30 min after treatment (Figure 7C) and even more markedly after
24 hr (Figure 7D). The massive leukemic cell death induced by
monocyte killing is shown in Figure 7E. Transwell experiments,
performed by seeding PBMCs from CLL patients depleted of
monocytes, showed that CLL death is partially dependent on
cell-cell contacts (Figure 7F).
We then evaluated the expression of key effector molecules
involved in cell death mechanisms in human primary leukemic
cells. To this aim, we purified by magnetic negative selection
leukemic cells from PBMCs of 24-hr-clodrolip cultures and un-
treated control cultures. We observed a significant upregulation
of FAS in all the treated samples analyzed (Figure S6A, n = 3).
Besides FAS, we observed the upregulation of TNFR1, FADD,
BID, and TRAIL-R2 in one patient’s sample (Figure S6B), sug-
gesting that several pathways of cell death (e.g., FAS/FASL,
TRAIL, and TNF) may be involved also in human primary CLL
cell killing induced by monocytes/macrophages.
To investigate the involvement of TNF and TRAIL in the
mechanism of leukemia cell death, we utilized etanercept and
a blocking anti-human TRAIL-R2 mAb (Germano et al., 2013).
As shown in Figures S6C and S6D, in three out of four samples,
the leukemic cell depletion induced by clodrolip was reduced
when TNF (Figure S6C) and TRAIL signaling (Figure S6D) were
blocked. To conclusively test the efficacy of a macrophage
targeting strategy on primary cells from CLL patients, PBMCs
were treated with anti-human CSF1R mAb (Figure 7G). We
observed a relevant depletion of both CD14+ monocytes and
leukemic B cells after 48 hr. More strikingly, the leukemic cell
depletion increased significantly when the anti-human CSF1R
mAb was associated to GA101 (Figure 7G).
Together, these findings indicate that macrophage killing
either restores CLL sensitivity to apoptosis or directly induces
their death. They further support the rationale translating these
findings into combination therapies.
DISCUSSION
All relevant events inCLLoccur in permissive tissuemicroenviron-
ments where different cell types influence the disease natural his-
tory, account for its clinical heterogeneity, and provide the basis
for identifyingnovel treatment targets.Weunambiguouslydemon-
strate, at the molecular and functional level, that malignant lym-
phocytes critically depend on the support of TAMs and provide
the proof of principle that the manipulation of leukemic cell/TAM
interactions may help designing therapeutic strategies for CLL.
Whole-genome transcriptional analysis indicates that BM
monocytes/macrophages exposed to leukemic cells in vivo
are enriched for specific genes involved in monocyte/macro-
phage-B cell interaction, inflammation, and transcription func-
tion. Likewise, the leukemic cell transcriptome is modified
upon interaction with the BM microenvironment (Figure S7).
The upregulation of Saa3 on monocytes/macrophages high-Cell Rlights the relevance of an inflammatory microenvironment in
leukemia engraftment and progression. SAA3 is known to attract
monocytes/macrophages, and it may cooperate with inter-
leukin-10 (IL-10) to promote M2-skewed macrophage accumu-
lation (Hao et al., 2012; Hiratsuka et al., 2008; Mantovani et al.,
2004), ultimately attracting leukemic cells. Notably, we found
several chemokines (e.g., CCL2, CCL17, and CCL22) upregu-
lated in leukemic MEC1 cells consistent with previous gene
expression studies of leukemic cells from CLL patients (Burger
et al., 2009; Herishanu et al., 2011). In keepingwith its expression
in human NLCs (Filip et al., 2013), the upregulation of ICAM1 in
human classical monocytes was particularly relevant. Inhibition
of ICAM1 in vivo confirmed its role in the interaction of CLL cells
with CD11b+ cells. We also observed an upregulation of several
known CLL players: CXCR4 and CXCR5 (Burger et al., 2000;
B€urkle et al., 2007);NOTCH1 (Puente et al., 2011), which is asso-
ciatedwith poor prognosis (Fabbri et al., 2011) andwas shown to
improve leukemic cell survival and resistance to apoptosis (Ar-
ruga et al., 2014); BIRC3, a prognostic factor (Cortese et al.,
2014) contributing to drug resistance (Rossi et al., 2012);
and PTEN, involved in molecular pathology (Leupin et al.,
2003), which may represent a further prognostic factor (Beldjord
et al., 2014). An unexpected finding was the downregulation
of RNASET2 transcript in leukemic cells. We previously
demonstrated that in ovarian tumorigenesis RNASET2 onco-
suppressive activity is associated with in vivo recruitment of
macrophages (Acquati et al., 2011) and that its loss of function
induces a microenvironment imbalance toward M2 tumorigenic
macrophages, with consistent depletion of anti-tumorigenic
M1 macrophages (Acquati et al., 2013). Our present finding
suggests the possibility that RNASET2 may have a similar role
also in leukemogenesis. Another intriguing observation is the
upregulation of CEBPB in CLL cells hinting at a possible role
for this transcription factor, as recently described for C/EBPa
in acute myeloblastic leukemia (Roe and Vakoc, 2014). Overall,
the scenario emerging from mouse findings (Figure S7) empha-
sizes the BM as a critical niche for the leukemic clone to engraft
and progress with the help of monocytes/macrophages. In
turn, leukemic infiltration induces changes of myeloid function
during leukemia development and progression. Our data on
the anti-CSF1R mAb, known to prevent the formation of new
macrophages by inducing apoptosis or inhibiting monocyte dif-
ferentiation, substantiate the dependence of the leukemic clone
on monocytes/macrophages especially in the BM niche, where
normally CSF1 induces differentiation and maturation of mono-
cytes (MacDonald et al., 2010; Ries et al., 2014).
The proof of principle that monocyte/macrophage depletion
results in an anti-leukemic effect was obtained by clodrolip
killing. The results obtained with the therapeutically relevant
anti-CSF1R mAb paralleled those obtained with clodrolip. In
different mouse models macrophage targeting impairs CLL
cell engraftment and, even more interestingly associates with a
striking anti-leukemic effect and a significant improvement of
mouse survival. The depletion of the monocyte/macrophage
pool goes along with the apoptosis of leukemic cells. Themolec-
ular mechanisms accounting for the leukemic cell death in vivo
appear to entail the RNA upregulation of key molecules of the
TNF pathway. Macrophage targeting sensitizes leukemic cellseports 14, 1748–1760, February 23, 2016 ª2016 The Authors 1757
to apoptosis via induction of TNF signaling and triggers their
death through a TNF-dependent mechanism.
As for solid tumors (Ries et al., 2014; Ruffell and Coussens,
2015), we found that CSF1R inhibition selectively targets TAMs
and alters the microenvironment toward an anti-leukemic pheno-
type. Furthermore,at variancewithclodrolip, theantibody induced
lymphocytosis, i.e., increased circulating leukemic cells express-
ing CD20 molecule, as it has been observed with BCR-targeting
drugs (Byrd et al., 2013). This observation suggested a treatment
strategy based upon the combination of two different antibodies,
one targeting TAMs and the other targeting CD20+ circulating
cells. Our in vitro findings on humanprimary CLL cells and the sur-
vival improvement of xeno-transplantedmice upon the combined
treatment corroborated the strong potential of this strategy.
The information obtained in mouse models was reproduced in
human samples at the preclinical level. The close proximity of
CD68+ macrophages to Ki67+ CLL cells in the lymph node prolif-
eration centers suggests that interfering with such interaction
might actually provide an amplification of the death signal. As
MEC1 cells, purified primary leukemic cells are also unaffected
by clodrolip treatment in vitro, which causes a marked depletion
of CLL cells only in the presence of CD14+ monocytes, confirm-
ing the monocyte/macrophage dependency of human leukemic
cells. FAS, a member of the TNFR family, was found upregulated
in human primary CLL cells exposed to clodrolip, together with
other keymolecules of the FAS/FASL, TNF, and TRAIL pathways
of cell death. Primary CLL cells do not express TNF receptors
in vivo (Digel et al., 1990), but cytokines such as IL-2 are known
to influence their expression (Digel et al., 1990). It is thus
conceivable that in our system macrophages undergoing rapid
and massive apoptosis may release cytokines and growth fac-
tors capable of upregulating TNF receptors on leukemic cells
and of restoring their sensitivity to apoptosis. This possibility is
corroborated by our findings upon TNF-blocking via etanercept.
In conclusion, our results indicate that CLL cell growth in vivo
is critically dependent on the support of TAMs and show the
tangible positive effects of manipulating such support. The pos-
sibility of utilizing drugs and monoclonal antibodies currently in
early or advanced clinical development may pave the way to
novel treatment approaches in CLL. As an example, our results
suggest the possibility of extending to CLL the use of the drug
trabectedin, which targets and kills macrophages via the TRAIL
receptor and has shown promising results in solid tumors (Ger-
mano et al., 2013). Furthermore, our findings on CSF1R inhibition
indicate that the clinical use of this type of antibody, possibly in
combination with anti-CD20 mAb, is more than worth exploring
in CLL. Finally, as the relevance of the inflammatory environment
is emerging in different B cell tumors (Hope et al., 2014), it can be
predicted that targeting the critical role of TAMs will not be
restricted to CLL; rather, it will become a strategy generally
applicable to chronic B cell malignancies.EXPERIMENTAL PROCEDURES
Mice
Allmicewere housedandbred in a specificpathogen-freeanimal facility, treated
in accordance with the European Union guidelines and with the approval of the
San Raffaele Scientific Institute Institutional Ethical Committee. Rag2/gc/1758 Cell Reports 14, 1748–1760, February 23, 2016 ª2016 The Authmice on BALB/c background were kindly provided by CIEA and Taconic,
Em-TCL1 transgenic mice on a C57BL/6 background were kindly provided by
Dr. Byrd, and wild-type C57BL/6 mice were supplied by Charles River Labora-
tories.Macrophage fas-induced apoptosis (MAFIA) transgenicmice, expressing
a bicistronic mRNA encoding both EGFP and transgenic cytoplasmic FAS
domains under the control of the c-fms promoter (Burnett et al., 2004), were
purchased from Jackson Laboratory. B6Smn.C3-Faslgld/J mice carrying a null-
function mutation of the Fasl gene were purchased from Jackson Laboratory.
Cells and Reagents
Human primary samples were obtained from RAI stage 0-1 CLL patients, after
informed consent as approved by the Institutional Ethical Committee (protocol
VIVI-CLL) of San Raffaele Scientific Institute (Milan, Italy) in accordance with
the Declaration of Helsinki.
The MEC1 CLL cell line was obtained from Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ) and cultured in RPMI 1640medium
(Invitrogen) with 10% fetal bovine serum and gentamicin (15 mg/ml; Sigma-
Aldrich). Clodrolip and phosphate buffer solution liposomes were purchased
from ClodLip B.V. Anti-mouse CSF1R antibody 2G2 and anti-human CSF1R
antibody emactuzumab (RG7155) (Ries et al., 2014) were provided by Roche
Innovation Center Penzberg, Germany. Anti-human CD20 GA101 (Mo¨ssner
et al., 2010) was provided by Roche Innovation Center Zurich, Switzerland.
In Vivo Studies
For xenograft studies, 8-week-old Rag2/gc/ mice were challenged either
i.v. or s.c. with 103 106 MEC1 cells in 0.1 ml saline through a 27G needle. De-
pending on the experiments mice were injected with clodrolip, anti-mouse
CSF1R mAb, or anti-human CD20 GA101 mAb. For transgenic transplantation
studies, C57BL/6male mice were challenged i.p. (day 0) with 103 106 cells pu-
rified from the spleen of leukemicmale Em-TCL1 transgenicmice. Depending on
theexperiments,micewere treatedwith clodroliporanti-CSF1RmAbatdifferent
doses and schedules. For detailed doses/schedules and functional studies with
etanercept and blocking mAbs, see Supplemental Experimental Procedures.
Murine Cell Preparations
PB, PE, SP, and femurs were collected from mice and cells were isolated.
Erythrocytes from BM, PE, SP, and PB samples were lysed by incubation for
5 min at room temperature in ammonium chloride solution (ACK) lysis buffer
(0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM Na2EDTA [pH 7.2–7.4]). After
blocking fragment crystallizable (Fc) receptors with Fc block (BD Biosciences)
for 10 min at room temperature, cells from PB, BM, PE, and SP were stained
with the antibodies (15 min at 4C) listed in Supplemental Experimental Proce-
dures and analyzed with a Beckman Coulter FC500 flow cytometer. Absolute
numbers were obtained by multiplying the percentage of the cells by the total
number of splenocytes, peritoneal cells, or BM cells flushed from one femur
(except for Figures 1B–1E, where the absolute number refers to the total BM
cells flushed from both femurs and tibias).
In Vitro Cultures and Cell-Depletion Assays from CLL Samples
Fresh PBMCs from untreated CLL patients were seeded, as triplicates, at 33
106 cells/ml in culture medium and treated with clodrolip or PBS liposomes
(100, 500, or 1,000 mM) for 30 min and 24 hr in the presence or absence
of etanercept (10 mg/ml), a TNF-a antagonist from Pfizer, or anti-TRAIL-R2 (hu-
man, 1 mg/ml) mAb (HS201) from Adipogen AG. For CSF1R inhibition studies,
PBMCs from CLL patients were treated 48 hr with anti-human CSF1R mAb
(1–10 mg/ml) or with anti-human CSF1R mAb + anti-CD20 mAb GA101
(10 mg/ml). The specific percentage of remaining leukemic CD19+CD5+ or
CD14+ cells in treated samples was calculated as (absolute number in treated
samples/absolute number in control samples) 3 100. For each condition, the
absolute number of remaining cells was calculated as total viable cell number
(trypan blue exclusion determination)3%of viable cells (flow cytometry deter-
mination). Then, specific cell depletion was calculated as follow: 100%spe-
cific remaining cells, as described previously (Laprevotte et al., 2013).
Histopathology and Immunohistochemistry
Tissues were fixed in 4% formalin for 12 hr, then embedded and included in
paraffin wax. Sections (5 mm thick) were cut and stained with H&E accordingors
to standard protocols. Microscopic specimens were evaluated by a patholo-
gist in a blinded fashion. For immunohistochemistry, see Supplemental Exper-
imental Procedures.
Gene Expression Profiling Analysis
BMmicroenvironment cellswere flushed frommice femurs and separated from
leukemic MEC1 cells, which were positively selected by human anti-CD19
beads and blocked on Miltenyi MS columns. hCD19 cells were secondary
enriched of monocytes/macrophages by depletion of T, natural killer, dendritic
cells, progenitors, granulocytes, and red blood cells with an EasySep negative
selection monocyte enrichment kit on an EasySep Magnet (STEMCELL
Technologies), following the manufacturer’s indications. RNA extraction was
performed using RNeasy Mini Kit (QIAGEN). 200 ng total RNA samples was
processed using an Illumina TotalPrep Amplification kit (Ambion Life Technol-
ogies), strictly adhering to the manufacturer’s protocol. Subsequently, biotin-
labeled cRNA was hybridized on a MouseWG-6 v2.0 Expression BeadChip
(harboring probes for 45,000 transcript) or HumanHT-12 v4 BeadChip
(harboring probes for 47,000 transcript) (Illumina) for 16 hr, followed by
Cy3 staining. Following hybridization, the BeadChip underwent a washing
and streptavidin-Cy3 (GE Healthcare Bio-Sciences) conjugate staining proto-
col. Once the BeadChip was processed it was scanned with an Illumina
BeadArray Reader. In brief, arrays were scanned on a BeadScan instrument,
and fluorescence intensities were extracted and summarized using the
BeadStudio software (Illumina), resulting in a set of summarized fluorescence
measurements. For detailed microarray analysis, see Supplemental Experi-
mental Procedures.
Statistical Analysis
Statistical analyses were performed with the use of the Student’s t test. Data
are expressed as mean ± SD, and comparison of growth curves was consid-
ered statistically significant for p < 0.05. Comparison of survival curves was
performed with the use of the log-rank test. For microarray analysis, see Sup-
plemental Experimental Procedures.
ACCESSION NUMBERS
The accession numbers for the GEP human and mouse studies are GEO:
GSE57787 and GSE57785, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, one table, and three movies and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2016.01.042.
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